GT Biopharma, Inc.
GTBP
$1.14
$0.000.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 38.06% | -54.56% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.69% | -48.66% | |||
| Operating Income | 21.69% | 48.66% | |||
| Income Before Tax | -84.66% | 79.44% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -84.66% | 79.44% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -84.66% | 79.44% | |||
| EBIT | 21.69% | 48.66% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -65.52% | 80.21% | |||
| Normalized Basic EPS | 31.66% | 54.75% | |||
| EPS Diluted | -65.52% | 80.21% | |||
| Normalized Diluted EPS | 31.66% | 54.75% | |||
| Average Basic Shares Outstanding | 18.20% | 3.88% | |||
| Average Diluted Shares Outstanding | 18.20% | 3.88% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||